Next Article in Journal
Two Cases of Angioimmunoblastic T-Cell Lymphoma with Concomitant Positive Serology for Acute Epstein-Barr Virus Infection
Previous Article in Journal
Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 9
Issue 3
10.4081/hr.2017.7078
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment

by
Kalman Filanovsky
1,2,* and
Lev Shvidel
1,2
1
Department of Hematology, Kaplan Medical Center, Rehovot 76100, Israel
2
Hadassah and Hebrew University Medical School, Jerusalem P.O. Box 12272, Israel
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(3), 7078; https://doi.org/10.4081/hr.2017.7078
Submission received: 4 February 2017 / Revised: 25 March 2017 / Accepted: 18 April 2017 / Published: 26 September 2017

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Ibrutinib (Imbruvica) is a first-in-class oral inhibitor of Bruton’s tyrosine kinase (BTK), an essential enzyme in B-cell receptor signaling pathway [...]
Keywords: lymphoma; ibrutinib; chronic renal failure lymphoma; ibrutinib; chronic renal failure

Share and Cite

MDPI and ACS Style

Filanovsky, K.; Shvidel, L. Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment. Hematol. Rep. 2017, 9, 7078. https://doi.org/10.4081/hr.2017.7078

AMA Style

Filanovsky K, Shvidel L. Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment. Hematology Reports. 2017; 9(3):7078. https://doi.org/10.4081/hr.2017.7078

Chicago/Turabian Style

Filanovsky, Kalman, and Lev Shvidel. 2017. "Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment" Hematology Reports 9, no. 3: 7078. https://doi.org/10.4081/hr.2017.7078

APA Style

Filanovsky, K., & Shvidel, L. (2017). Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment. Hematology Reports, 9(3), 7078. https://doi.org/10.4081/hr.2017.7078

Article Metrics

Back to TopTop